
October 25, 2014	Web Version \| Share with a colleague \| eNews Subscribe	You are subscribed to the FormularyWatch eNews

Unprecedented efficacy of latest HER2-targeting agents can extend life but at significant cost

The new generation of HER2-targeting agents are drastically changing the outlook for patients with HER2-positive breast cancer, and oncologists will be eager to maximize these treatment options. » Read more on key therapies of the HER2-positive breast cancer armamentarium

Public-private partnerships in advancing Ebola treatment pipeline

Currently, there are no FDA-approved vaccines or drugs for Ebola virus. The need for effective therapeutic approaches is increasingly vital, yet the research dollars have not been forthcoming. » Read how healthcare policymakers can help alleviate risks, up-front costs associated with drug development

#icymi